The following is a description of a study from one of the many researchers that our organization has funded.
Karen Costenbader, M.D.
Brigham and Women’s Hospital
Dr. Costenbader is conducting a randomized, double-blind study of 50 lupus patients to determine the appropriate dosing level of Pravastatin, an oral medication proven to reduce cholesterol levels in the general population. No studies have been done on pravastatin’s effect on lupus patients or those receiving steroids. High cholesterol levels are common in lupus patients (at least partially resulting from their treatment with steroids). Establishing the doses of pravastatin necessary to reduce cholesterol in lupus patients will contribute to a strategy of comprehensive care for this high-risk group.
You may return to the list of research that we have funded.